Study #2016-0727
Long-term follow-up study of patients who have previously been exposed to UCART19/ALLO-501 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)
MD Anderson Study Status
Not Accepting
Treatment Agent
UCART19 follow-up
Description
The purpose of this study is to evaluate the long-term safety and efficacy of UCART19 administration to patients with advanced lymphoid leukemia.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Lymphoid Leukemia
Study phase:
Phase I
Physician name:
Nitin Jain
Department:
Leukemia
For general questions about clinical trials:
1-866-419-2881
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.